CLIENT ALERT: Federal Reclassification of Medical Marijuana Signals Shift for State-Licensed Operators

On April 23, 2026, the Acting Attorney General signed an order reclassifying FDA-approved marijuana products and state-licensed medical marijuana under the Controlled Substances Act from Schedule I to Schedule III. This action is a direct result of the White House’s December 18, 2025, Executive Order, which mandated federal agencies to accelerate the administrative process to reschedule marijuana under the Controlled Substances Act. While the order stops short of full de-scheduling, it marks one of the most consequential federal policy shifts affecting the cannabis industry in decades.

WHY THIS MATTERS

One of the most immediate and impactful changes resulting from this Order relates to federal taxes. Under Internal Revenue Code § 280E, businesses involved with Schedule I or II substances cannot deduct ordinary business expenses, which has historically resulted in significantly higher effective tax rates for cannabis operators. Because Schedule III substances are not subject to § 280E, this rescheduling may allow licensed medical marijuana operators to take standard business deductions for the first time. If implemented as expected, this change could substantially reduce tax burdens and improve profitability, though additional guidance from the IRS will be needed to confirm how and when these benefits apply.

The order also introduces additional regulatory changes. It creates an expedited pathway under 21 C.F.R. Part 1301 for state-licensed medical marijuana operators to obtain DEA registration as manufacturers, distributors, and/or dispensers. It also confirms that researchers may use marijuana sourced from state-licensed programs without facing federal enforcement.

WHAT COMES NEXT

While the order is a major step for licensed medical marijuana operators, its full impact hinges on forthcoming rulemaking and agency guidance. Notably, Attorney General Todd Blanche has also scheduled a hearing for June 29, 2026, to consider removing cannabis from the Controlled Substances Act entirely. If pursued, this would extend beyond medical marijuana to include adult-use cannabis.

Our firm closely monitors these developments and advises clients navigating the rapidly evolving cannabis regulatory landscape. Panza Maurer assists clients with the administrative, regulatory, and business processes required to obtain a Medical Marijuana Treatment Center (“MMTC”) license in the State of Florida, and we remain focused on helping businesses stay compliant as federal and state frameworks continue to change. If you have any questions about how these developments may affect your operations or future plans, please contact Panza Maurer.